Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
INC Research
Latest News
Last days for Pfizer's Celebrex
One of Pfizer's best-known medicines, pain-killer Celebrex will face generic competition for the first time on the PBS from December 1 as will GSK's Panadol Osteo.
Ministers call time on ANZTPA
The TGA and Medsafe will be going their own ways as the health ministers of Australia and NZ declare an official end to the second attempt to create a joint regulator.
Symbion opens $40m logistics hub
Symbion MD Patrick Davies claims its new state-of-the art $40m distribution centre in Melbourne is the most advanced pharmaceutical facility in the world today.
Bayer's Sargent back to lead ASMI
Mark Sargent, GM consumer care ANZ at Bayer, has been re-elected as ASMI president, marking his third year in the role.
Sigma repudiates competition panel
Wholesaler Sigma has come out again in support of pharmacy, rejecting the Competition Policy Review panel's recommendation to remove ownership and location rules.
Cost of drug development skyrockets
Getting a new prescription medicine from bench to market approval now costs over US$2.5 billion, more than double the cost in 2003 says a study of over 100 drugs from 10 pharmacos.
Govt missing billions in switch savings
Australian drug regulation is too focused on protecting a few potential drug misusers, preventing the government from realising billions in savings that could come from more down-scheduling.
AFT beats GSK in TM stoush
GSK's Panadol Osteo franchise is under assault on several fronts but this time it has lost the fight against AFT Pharmaceuticals over an application to trademark 'Paracetamol Osteo-Tab'.
Asthma meds too expensive
Asthma expert Professor Guy Marks says the high cost of daily preventer medications in Australia makes them unaffordable for many sufferers, leaving them liable to attacks.
Vytorin efficacy finally proven
MSD's Vytorin has been shown to lower the risk of future cardiovascular problems in high-risk patients with acute coronary syndrome.
TGA could have to save close to $1bn
The TGA welcomes the government's red tape review even though it expects to be asked to make significant savings, especially in the first year.
James hails China-Aust FTA
MA CEO Tim James has welcomed the ending of tariffs on Australian-made pharmaceuticals in the China-Aust FTA as 'another open door' to industry growth.
More ad strife for Chem Warehouse
The Victorian Pharmacy Guild and National Pharmacies have written to the ACCC asking it to investigate Chemist Warehouse promotion of discounts, with the Guild describing it as a 'matter of urgency'.
GSK tops global meds access poll
The Access to Medicine Index for 2014 has put GSK top of the list for companies which are doing the most to improve access to drugs in developing countries.
No gain in dismantling pharmacy
The Pharmacy Guild says it has strong evidence that ending pharmacy location and ownership rules as recommended by the government's competition review would back-fire, leaving consumers seriously worse off.
Studies back MSD hep C therapy
Promising results from two US-led studies published by The Lancet will support MSD's FDA drug application next year for hep C antiviral grazoprevir/elbasvir, with or without ribavirin.
Red tape panel sets out review basics
Responsibility for medicine regulation should remain with the Commonwealth, even though 'trusted' overseas assessments might be accepted, say independent experts reviewing the drug regulation system.
'Half-truth' gives GSK a win in court
In defending its Panadol franchise, GSK has won access to documents used by Pharmacor to register Osteomol 665 Paracetamol on the ground that Pharmacor may be telling a 'half-truth' about bioequivalence.
GPs medicating more mental illness
GPs are managing more mental health issues than ever before and prescription medication, the most common form of management, is increasing at an annual average of 0.8 per cent.
CSL testing heart attack therapy
CSL has launched a phase IIb clinical study of novel high-density lipoprotein based therapy CSL122 with hopes of addressing an unmet need to reduce heart attacks following hospital admission.
Older hep C drugs highly effective
As Gilead ramps up the case to approve its latest Hep C breakthrough Harvoni, JAMA reports a cumulative 10-year overall survival rate of 91.1 per cent in patients treated with older, cheaper drugs.
GSK nixes CMI leaflet inserts
GSK has revealed that it will no longer be providing Consumer Medicines Information leaflets with its medicines but says it is not the first company to do so.
Open Forum
Is switch a turn-off for Aust industry?
The week's annual ASMI conference heard a lot about how Australia is lagging when it comes to moving tried and true treatments from the script pad to the consumer's shopping list but can the regulatory blockages be cleared?
Working Life
Gender equality: why Merck Serono is a winner
Merck Serono's appearance on the inaugural Employer of Choice for Gender Equality list is not by chance, gender equality is something the company 'lives and breathes' says MD Andre Musto.
Pipeline Monitor
Roche wins expanded approval for Avastin
The FDA has expanded the label for Roche's Avastin to platinum-resistant, recurrent, epithelial ovarian, fallopian tube or primary peritoneal cancer.
Approvals Action
First threat to Sanofi heart drug
Sanofi's angina treatment Ikorel is facing its first competitive threat in the form of Ikotab, registered during the week by Aspen, while further competition has emerged for anti-depressant Pristiq.
Special Report
Top 20 brands, latest PBS roundup
Some interesting trends are evident among the top 20 PBS products for the quarter to September 30 including something of a turnaround for Novartis' Lucentis.
FREE Content
Events & Conferences
Pharma in Focus Jobs
Ascott Sales
DB Schenker